A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B

BACKGROUND/AIM: Acute-on-chronic liver failure (ACLF-B) in spontaneous reactivation of chronic hepatitis B (SR-CHB) has high mortality. Tenofovir disoproxil fumarate (TDF) improves survival by ~40% in ACLF-B but is potentially nephrotoxic. Combining telbivudine (LDT) with TDF may negate this risk an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jindal, Ankur, Vyas, Ashish, Sharma, Manoj, Kumar, Guresh, Sarin, Shiv K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784432/
https://www.ncbi.nlm.nih.gov/pubmed/31044748
http://dx.doi.org/10.4103/sjg.SJG_537_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784432/
https://www.ncbi.nlm.nih.gov/pubmed/31044748
http://dx.doi.org/10.4103/sjg.SJG_537_18

Ejemplares similares